share_log

Sensei Biotherapeutics Slashes Workforce, Closes R&D Site

Sensei Biotherapeutics Slashes Workforce, Closes R&D Site

Sensei Biotherapeutics 裁员，关闭研发基地
Benzinga Real-time News ·  2022/12/08 10:41
  • Sensei Biotherapeutics Inc (NASDAQ:SNSE) announced a streamlining and realignment of resources.
  • The company will close its Boston research site and reduce its workforce by approximately 40% to extend Sensei's estimated cash runway into the second half of 2025 versus Q1 of 2025 expected earlier.
  • The company will maintain its Rockville, Maryland research facility, where antibody discovery and production in support of its lead program SNS-101 and other TMAb programs is conducted while maintaining a smaller business office in the Boston area.
  • With these announcements, Robert Pierce, Sensei's Chief R&D Officer, will move to a consulting role as a Science Fellow, and Edward van der Horst, Sensei's SVP, Biologics Discovery & Early Development, has been promoted to Chief Scientific Officer.
  • Sensei continues to advance SNS-101 through investigational new drug-enabling studies and intends to submit an Investigational New Drug application (IND) in or before April 2023.
  • Price Action: SNSE shares are down 2.60% at $1.50 on the last check Thursday.
  • SENSEI生物治疗公司纳斯达克(Sequoia Capital：SNSE)宣布精简和调整资源。
  • 该公司将关闭其波士顿研究网站，并裁员约40%，以将Sensei预计的现金跑道延长至2025年下半年，而此前预计2025年第一季度。
  • 该公司将保留其位于马里兰州罗克维尔的研究设施，在那里进行抗体发现和生产，以支持其领先计划SNS-101和其他TMAb计划，同时在波士顿地区保留一个较小的商业办事处。
  • 宣布这些消息后，Sensei的首席研发官罗伯特·皮尔斯将担任科学研究员的咨询职务，Sensei负责生物制品发现和早期开发的高级副总裁Edward van der Horst已晋升为首席科学官。
  • SENSEI继续通过研究性新药使能研究推进SNS-101，并打算在2023年4月或之前提交研究性新药申请(IND)。
  • 价格行动：瑞士证券交易所股价周四收盘时下跌2.60%，至1.50美元。
声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发